# Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conf-a0a234d5
Ticker: ACRS
Company: Aclaris Therapeutics
Source: Aclaris Therapeutics
Published: 2026-05-28 12:30 EST
## Summary

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference...

## Article Body
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com . The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn .

Aclaris Therapeutics Contact:

Will Roberts Senior Vice President Corporate Communications and Investor Relations (484) 329-2125 wroberts@aclaristx.com
## Recent Company News
- 2026-05-28 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conf-a0a234d5) — Source: Aclaris Therapeutics
- 2026-05-08 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-bank-of-america-healthcare-confe-33f392b6) — Source: Aclaris Therapeutics
- 2026-05-07 10:59 EST — [Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2026-financial-results-and-provides-c-c157b37c) — Source: Aclaris Therapeutics
- 2026-04-28 10:30 EST — [Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-announces-positive-full-top-line-first-in-human-results-fro-968484cf) — Source: Aclaris Therapeutics
- 2026-04-27 20:45 EST — [Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-provide-clinical-update-on-key-biologic-and-oral-inhibit-c67a7f91) — Source: Aclaris Therapeutics
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)